Globe says Opsens boosted to "strong buy"From this morning Globe & Mail just in case some have miss the info !
Globe says Opsens boosted to "strong buy"
2021-11-25 08:36 ET - In the News
The Globe and Mail reports in its Thursday edition that Raymond James analyst Rahul Sarugaser has upgraded Opsens to "strong buy" from "outperform." The Globe's David Leeder writes that Mr. Sarugaser continues to target the shares at $6. Analysts on average target the shares at $4. Mr. Sarugaser says he has a "higher than usual degree of confidence" in the "positive performance and safe operations" of Opsens. It posted its fourth quarter result on Tuesday. Mr. Sarugaser says he was "extremely pleased" with the 20-patient safety trial for the company's new guidewire for transcatheter aortic valve replacement and is now targeting commercial launch in 2022. He says in a note: "While data has not yet been published, we have several reasons to believe that Opsens saw positive data from its 20-patient FIH safety trial: 1. Companies do not apply for marketing clearance if clinical data reveals poor safety; 2. The trial was open label, with Opsens's team present for every single procedure, and there is no follow-up required (i.e. their understanding of endpoint success was immediate); 3. A portion of the clinical trial data, which was all positive, was reported by KOLs at the TCT conference earlier this month."
«